LONGEVITY RESEARCH

OUR COMMITMENT TO RESEARCH

As a community of longevity experts, doctors, and scholars, AgelessRx is fully committed to the invaluable role research plays in medicine and the limitless opportunities it presents for the future.

 

In that spirit, AgelessRx is proud to play a leading role in discovering new, scientifically-proven treatment options that prevent age-related diseases and reverse age-related damage.

CURRENT RESEARCH PROJECTS

Rapamycin Trial

Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)

469229-research-science.png
pill icon.png
DNA.png

Rapamycin is an FDA-approved antifungal agent, most used to prevent organ transplant rejection. Rapamycin targets the mTOR signaling pathway, which is associated with many aging-related diseases. 

PEARL is a double-blind, randomized, placebo-controlled trial. Notably, it is the first nationwide telemedicine trial and the first large-scale intervention trial on longevity. PEARL is proudly sponsored by AgelessRx and affiliated with the University of California.

Post-COVID-19 Trial

Pilot Study into Low Dose Naltrexone (LDN) and NAD+ for Treatment of Patients with Post-COVID-19 Syndrome

469229-research-science.png
pill icon.png
DNA.png

Proudly sponsored by AgelessRx, this double-blind placebo-controlled pilot study will assess the use of Low Dose Naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19).

AgelessRx will enroll over 60 people (must have had a positive test for SARS-CoV-2 1-4 months before enrollment) for a 12-week study.  Patients will receive LDN and NAD+ treatment or a corresponding placebo tablet and patch (control group) for the 12-week duration.